Margaret Olinger - 27 Dec 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Commercial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
27 Dec 2023
Net transactions value
+$9,250
Form type
4
Filing time
29 Dec 2023, 16:07:35 UTC
Previous filing
14 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $9,250 +25,000 +10% $0.3700* 276,108 27 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Options Exercise $0 -25,000 -36% $0.000000 44,577 27 Dec 2023 Common Stock 25,000 $0.3700 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option are fully vested and exercisable.